Novel source of hyaluronic acid from camel's limbs
Patent Information
- Application Number
- PCT/IB2025/052849
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-03-18
- Publication Date
- 2026-09-24
Smart Images
Figure IB2025052849_24092026_PF_FP_ABST
Abstract
Description
Title of Invention: Novel Source of Hyaluronic Acid from Camel's LimbsFIELD NVENTION
[0001] For the first time, this innovation pertains to a new source of the substantial amounts of HA found in camel limbs. In this innovation, hyaluronic acid material from a unique sourcecamels' limbs-is extracted, isolated, and partly purified. The present invention relates to a hyaluronic acid (HA) composition with a controlled molecular weight distribution. The invention further provides methods for characterizing HA using Nuclear Magnetic Resonance (NMR), Fourier Transform Infrared Spectroscopy (FTIR),and Size Exclusion Chromatography-Multi-Angle Laser Light Scattering (SEC-MALLS), and. The HA composition is suitable for pharmaceutical, cosmetic, and biomedical applications.BACKGROUND OF THE INVENTION
[0002] Hyaluronic acid (HA) is a polymer of disaccharides, also known as hyaluronan. N-acetyl glucosamine (GIcNAc) and glucuronic acid (GlcUA) are the linear, unbranched, polyanionic disaccharide units that make up HA. These units are alternatively linked by (beta-1 ,3)- and (Beta-1 ,4)-glycosidic bonds1. The extracellular matrix of soft connective tissue naturally contains the glycosaminoglycan hyaluronic acid (HA). It is a naturally occurring component of the extracellular matrix that is highly hydrated and is found in brain, connective and epithelial tissue. As HA is a non-sulphated biomaterial, it cannot attach to a nuclear protein during proteoglycan production, unlike other GAGs. The term "hyaluronic acid" was coined in 1934 by Meyer and Palmer, who isolated this biopolymer from a bovine eye2. They called it hyaluronic or vitreous and uronic acid I it is most concentrated in the synovial fluid of the joints and in the vitreous body of the eye3. Sources of hyaluronic acid (HA): In the decades that followed, scientists like Meyer found HA in a number of biological components, including skin, umbilical cords, vitreous humor, cockscombs and synovial fluid. In 1937, Kendall demonstrated that streptococci and other bacterial strains can produce HA4. In modern manufacturing, bacterial fermentation is a popular method of HA production. Enzymatic digestion, protein separation and a number of purification processes are often used to extract HA from cock combs. In these phases, ethanol often precipitates and re dissolves in sodium chloride solutions. First, the epithelium can be removed from the ridge, ground and treated with acetone. This may be followed by many ethanol and salt chloridetreatments. Several U.S. patents, including U.S. Pat. Nos. 5,316,926; 5,559,104; 4,141,973; 5,099,013; 5,166,331; 5,411,874; 5,925,626; and 4,784,990, outline specific methods for isolating and purifying HA, and are referenced here.
[0003] Due to its high degree of hydration, HA is most likely the reason for the high water content of some tissues, which increases their resistance to compression. The ability of hyaluronic acid to bind extra water than any other artificial or natural polymer is the basis for this function.
[0004] HA is widely used in dermal fillers, ophthalmic solutions, osteoarthritis treatments and tissue engineering. The molecular weight of HA has a direct influence on its viscoelastic properties, degradation rate and biocompatibility. While HA with a high molecular weight (>1 ,000,000 g / mol) has a longer in vivo stability, HA with a medium molecular weight (200,000 -1,000,000 g / mol) offers improved inject ability and biological interactions5. A balanced molecular weight distribution optimizes both stability and rheological performance. Existing HA formulations lack precise control of molecular weight, leading to variability in biomechanical and biological properties. The present invention overcomes these limitations by providing an HA composition with a controlled molecular weight distribution that ensures improved performance and reproducibility.
[0005] Whether a particular HA preparation forms an elastoviscous matrix under particular conditions depends on the size (molecular weight) of the individual molecules and the possibility of intermolecular interactions6. Another function of hyaluronic acid is to thicken the synovial fluid. A hyaluronic acid solution has a viscoelastic effect, that makes it rigid and elastic on impact, but easier to process during slow movements7. In young people, the shock-absorbing effect is very significant and strong. Hyaluronic acid (HA), a naturally occurring lubricant, is required for the synovial fluid to effectively lubricate the membrane8. In contrast to chondroitin sulphate, dermatan sulphate and keratin sulphate, whose solution viscosity is lower due to low water binding, the network-forming property is important in connective tissue9.
[0006] The molecular weight, physiological pH, and solution concentration all affect the HA's characteristics. Individual chains of a water-soluble polymer entangle and create a continuous network in solution at low concentrations, providing the system with interesting properties including strong viscoelasticity and pseudo plasticity that are unusual for a low concentration. Both bacterial fermentation and separation from natural tissue are two alternative manufacturing processes for HA, and each has unique properties that impact its use10.
[0007] Extracting HA from natural tissues such as cockscombs or umbilical cords preserves the natural glycosaminoglycan structure, which is very porous and disperses well in water. However, in order to eliminate proteins and other tissue components, this approach may requirecomplicated extraction and purification procedures. However, due to the nutrient-rich medium used in the manufacturing process, HA produced by bacterial fermentation often has higher levels of bacterial contamination. This type of HA usually contains high levels of bacterial proteins and endotoxins, so thorough purification is required to achieve pharmaceutical grade purity.
[0008] The additional purification required to remove impurities can drive up production costs, even though fermentation is a scalable and sustainable manufacturing process, especially for large volumes. These differences highlight the importance of selecting the right HA source according to the specific requirements of the intended application, whether for industrial, cosmetic or medical purposes.
[0009] HA, which is produced using a variety of established techniques or obtained from conventional materials, has several disadvantages. For example, it can lead to post-operative difficulties in eye surgery and can cause inflammatory reactions when used in animal therapies. Although these problems are often resolved or mitigated by further processing, this increases the price of HA that meets the necessary functionality and purity requirements.
[0010] The global market for hyaluronic acid was estimated to be around USD 9 billion as of 2023. It is anticipated to rise at a compound annual growth rate of around 7% between 2024 and 2029, reaching over USD 13 billion by that year. Growing senior populations, greater skincare consumer knowledge, and rising desire for less invasive aesthetic procedures are some of the factors driving this trend.
[0011] The extraction of hyaluronic acid from camel limbs has not been the subject of published research. Traditional sources such as rooster combs, bovine tissue and bacterial fermentation are the focus of most current research on HA extraction. Despite their unique physiology and ability to adapt to desert climates, camels have not been thoroughly investigated as a source of HA. In camels, HA may be present in significant amounts in the synovial fluid (in the joints), skin and other connective tissues. However, there are no previous reports on the extraction of HA from camel limbs or on the presence of HA in significant quantities in camels.
[0012] Therefore, new sources of HA with higher concentrations of naturally occurring HA are needed. In addition, HA from novel sources is needed as they do not have the same problems as HA from known sources, require less processing and / or offer more affordable ways to produce valuable HA products.SUMMARY OF THE INVENTION
[0013] The current innovation goes back to the first discovery that the limbs of camels contain considerable amounts of HA. The extraction of hyaluronic acid from a new biologicalsource, which has a distinct molecular weight distribution suitable for pharmaceutical, cosmetic and biomedical applications, is another aspect of the present invention. The HA composition is ideally suited for medical, tissue engineering, pharmaceutical and cosmetic applications due to this innovative extraction technique, which also improves purity, structural integrity and bioactivity.
[0014] The extraction of hyaluronic acid from a new biological source that has a distinct molecular weight distribution suitable for intra-articular injections, joint lubrication and the treatment of osteoarthritis is another aspect of the present invention. By improving purity, structural integrity and bioactivity, this innovative extraction technique enhances the HA composition for use in pharmaceutical and medical applications.
[0015] Using methods for extracting HA from various starting materials, HA was recovered from raw camel limbs and partially purified after the existence of substantial levels of HA in the limbs was confirmed. Due to the controlled molecular weight distribution and biochemical properties of the composition, it is excellent for viscosity supplementation therapy, joint pain relief and mobility enhancement. The invention provides a hyaluronic acid composition characterized by a predominant high molecular weight fraction (approximately 1,047 kDa, approximately75.9%) while maintaining a controlled intermediate fraction. The composition is characterized by SECMALLS, NMR and FTIR.
[0016] The inventors believe that this is the first detection of significant amounts of HA in camel limbs and that camel limbs could be a rich source of HA for various applications. Consequently, the current invention is a hyaluronic acid isolate that contains HA that was taken from the limbs of camels. A hyaluronic acid fraction is extracted from the camel's limbs to create the hyaluronic acid isolate. In one instance, the hyaluronic acid fraction is purified to yield an isolate of hyaluronic acid that contains the necessary amount of naturally occurring HA. This isolate can further be processed to yield hyaluronic acid of pharmaceutical or cosmetic quality.
[0017] The hyaluronic acid is ideal for use as a lubricant or moisturizing ingredient in eye drops or cosmetics, as an oral nutritional supplement, or as a topically administered treatment for joints damaged by osteoarthritis. Therefore, in another sense, the invention focuses on a method of administering an HA-rich composition of camel limb to a mammal suffering from a disease that would benefit from HA administration. The result of the present invention is a really good, practical product. HA can be provided alone or in combination with other naturally occurring medicinal components for use in compositions and treatments for mammals or both humans and animals.
[0018] Meat and milk are the dietary sources provided by camels. Worldwide, 3.3 million camels and camelids are killed each year for their flesh. A substantial amount of meat may be obtained from a camel corpse. Male Bactrian camel carcasses may weigh up to 650 kg, and maledromedary carcasses can weigh between 300 and 400 kg. A female dromedary's carcass weights between 250 and 350 kg, which is smaller than a male's11. This indicates the abundance of this source and the ease of access to it and cheap prices compared to other sources of HA.DETAILED DESCRIPTION
[0019] The current invention reports the presence of high concentrations of HA in camel's limbs and describes extraction, purification, and analysis of HA derived from camel's limbs.
[0020] The finding of substantial amounts of HA in camel limbs for the first time served as the foundation for the current idea. The hyaluronic acid substance from camel's limbs, a unique source, is extracted, isolated, and partially purified in this invention. Additionally, beneficial isolates and formulations are prepared based on the finding.
[0021] According to the inventors, camel limbs are a reliable supply of HA. Joint injections, injectable hydrogels for wound healing, dermal fillers, and biomedical hydrogels are just a few of the uses for this HA. Sample has the high sodium hyaluronate content (79.9%) Furthermore, Uronic acid content (38.6%), which means it retains more of its structural integrity and hydration properties.
[0022] The following table presents the key technical characteristics of the invention, providing a structured summary of its molecular weight distribution, biochemical composition, and analytical properties, Table 1:
[0023] [Table 1]>
[0024] Derived from camel limbs, the revealed hyaluronic acid (HA) composition provides improved purity, biocompatibility, and a regulated molecular weight profile. The stability and efficacy of HA are greatly increased by the extraction process, which makes it suitable for use in a variety of industries, including the pharmaceutical, cosmetic, and biomedical sectors. The HA composition is appropriate for tissue engineering and regenerative medicine in biomedical applications, including as biocompatible implants, artificial scaffolds, and wound healing. It is also advantageous in ophthalmic solutions for post-operative eye care and corneal hydration.
[0025] As a carrier for the regulated and prolonged release of active pharmaceutical ingredients (APIs), HA is an essential part of drug delivery systems in the pharmaceutical industry. Additionally, it is incorporated into injectable formulations for dermatological treatments and biocompatible hydrogel-based therapeutics.
[0026] The HA component is utilized in sophisticated dermatological formulations for skincare and cosmetic purposes in order to improve skin elasticity, deep hydration, and anti-agingeffects. Additionally, high-purity HA is used in personal care products including serums, lotions, and face masks to improve skin absorption. A high molecular weight HA fraction (approximately 1 ,047 kDa) with exceptional biophysical characteristics is produced by this extraction process, guaranteeing enhanced bioactivity and sustained effectiveness in the intended applications.
[0027] With improved purity, biocompatibility, and a regulated molecular weight profile, the revealed HA composition comes from a unique biological source. There are numerous important processes in the extraction process. First, the use of a yet untapped source with a high HA yield and exceptional structural integrity is guaranteed via biological source selection. Second, contaminants are eliminated while maintaining maximum bioactivity by purification methods as SEC chromatography, enzymatic digestion, and enhanced membrane filtering. Finally, the intended molecular weight distribution for joint applications is guaranteed by molecular weight optimization, which is accomplished by controlled de-polymerization or crosslinking.
[0028] A high molecular weight HA fraction (approximately 1,047 kDa) with excellent viscoelastic qualities is produced by this extraction process, guaranteeing improved joint lubrication and long-lasting therapeutic effectiveness. The revealed HA composition can be injected intra-articularly into synovial joints, such as the shoulder, hip, and knee, among others. Its efficacy in joint health applications is supported by a number of characteristics. Because the primary molecular weight peak (approximately 1 ,047 kDa) matches commercially available viscosupplement formulations used for joint injections, the molecular weight and lubrication qualities are maximized. Diffusion into cartilage and bioavailability are enhanced by the small molecular weight peak (approximately 37 kDa). An ideal compromise between extended joint residence duration and efficient lubrication is guaranteed by the bimodal molecular weight distribution.
[0029] Furthermore, the HA formulation's biological makeup improves joint function. For synovial fluid replacement, the high purity and biocompatibility are guaranteed by the sodium hyaluronate content (79.9%). The 38.6% uronic acid concentration promotes viscoelasticity and hydration, both of which are essential for cartilage health. The anti-inflammatory properties and stability of synovial fluid are facilitated by the 43.0% sodium glucuronate level.
[0030] Advanced analytical procedures are used to ensure the composition's structural integrity and biocompatibility. NMR study preserves the natural polymeric structure necessary for joint lubrication by confirming the existence of glucuronic acid and N-acetyl-glucosamine residues. Further supporting HA's function in lowering joint friction and inflammation is FTIR spectroscopy, which validates functional groups essential for water retention, flexibility, and biocompatibility.
[0031] There are several potential advantages and therapeutic uses for the HA composition. It is appropriate for intra-articular injection in individuals with joint pain and cartilage degradation,and it may be prepared as an injectable visco-supplement for the treatment of osteoarthritis. The formulation is a good option for orthopedic and rheumatic applications since it helps to reduce joint friction, improve mobility, and relieve pain.
[0032] The extraction process described herein provides enhanced production efficiency and higher yield compared to conventional methods, ensuring a more cost-effective and scalable approach to hyaluronic acid production.
[0033] Additionally, the HA composition's molecular weight distribution qualifies it for a range of biomedical uses, guaranteeing great effectiveness and functional flexibility across therapeutic and medical domains.EXAMPLES
[0034] Preferred embodiments of the invention are demonstrated by the following nonlimiting examples.EXAMPLE 1
[0035] The limbs of the camel were taken from the animal. Initially, the camel's limbs were detached from limbs body. After being gathered and wished, the camel's limbs were promptly wrapped in plastic bags and kept in cold storage. Later, camel limb samples were collected in order to extract and purify HA. After being pulverized, the samples were kept in acetone at 4°C for 24 hours. The extraction process began with dilapidation, which was carried out for 24 hours at 25°C in a solution of chloroform and methanol (2:1 , v / v).EXAMPLE 2
[0036] The tissues were dried up and hydrated in digestion buffer (100 mM sodium acetate pH 5.0, 5.0 mM cysteine and 5.0 mM disodium-EDTA) in the ratio of 2.0 mL of buffer to 100 mg of dry tissue. After hydration (24 h at 4°C), a solution of papain in digestion buffer (20 mg / mL) was added in the ratio of 0.5 mL to 100 mg of dry tissue. The mixture was incubated (24 h at 60°C), centrifuged at 3200 rpm for 30 min, and the supernatant was removed. The pellet was discarded.EXAMPLE 3
[0037] After adding 10% cetylpyridinium chloride (CPC) to the supernatant at a ratio of 0.25 mL to 100 mg of dry tissue, the mixture was allowed to sit at 25°C for 24 hours. 3.0 mL of 2.0 M NaCI and 100% ethanol (100:15 v / v) were used to wash the pellet after the sample was centrifuged (3200 rpm for 30 minutes) and the supernatant was disposed of. After adding absolute ethanol (2:1, v / v), the mixture was allowed to sit at -16°C for 24 hours. After centrifugation (3200 rpm for 30 min), the pellet was once again cleaned with 10 mL of 80%ethanol, and the supernatant was disposed away. The pellet was dried for 24 hours at 25 degrees Celsius after the solution was centrifuged once more (3200 rpm for 30 minutes) and the supernatant was disposed of.EXAMPLE 4
[0038] Fourier Transform Infrared Spectroscopy (FTIR) was used to confirm the functional groups and purity of the HA sample. The HA sample was analysed by infrared spectroscopy using Perkin Elmer FTIR Spectrometer (Spectrum Two) and wavelength oscillating from 4000 to 400 cm-1.
[0039] Totally, 11 numbers of peaks were observed similar for standard and sample within range. These FTIR results confirm the presence of key functional groups, ensuring HA integrity. The functional groups associated to each wave number were listed and tallied. (Table 2) and Fig 1.
[0040] [Table 2]EXAMPLE 5
[0041] Nuclear Magnetic Resonance (NMR) analysis confirmed the structural integrity and purity of hyaluronic acid (HA). The1H-NMR spectrum exhibited characteristic signals corresponding to glucuronic acid (GlcA) and N-acetyl-glucosamine (GIcNAc) residues, indicating the presence of [3-glycosidic linkages.
[0042] The1H-NMR spectra were obtained using a Varian Infinity Plus spectrometer operating at 300 MHz. A deuterated solvent was used as an internal reference for chemical shifts. Proton nuclear magnetic resonance (1H-NMR) is an effective technique for determining the location of hydrogen atoms in molecular structures.
[0043] Typically,1H-NMR spectra of organic compounds exhibit chemical shifts ranging from +14 to -4 ppm, influenced by spin-spin interactions between protons. The spectrum clearly demonstrates the presence of GlcA H-1p glycosidic linkages and GIcNAc H-1p glycosidic linkages, confirming the structure of HA (Figure 2).1H-NMR Results:• Chemical shift between 4.5 and 5.0 ppm corresponds to the anomeric proton of GlcA and GIcNAc.• Chemical shift between 3.0 and 4.0 ppm corresponds to the ring protons of the HA backbone.• Chemical shift at 2.0 ppm corresponds to the N-acetyl (-NHCOCH3) resonance of GIcNAc These results confirm that the HA retains native structural conformation and is free from degradation or chemical modifications.EXAMPLE 6
[0044] The HA composition was analyzed using Size-Exclusion Chromatography with MultiAngle Laser Light Scattering (SEC-MALLS) to determine the precise molecular weight distribution. Table3, Figure.3
[0045] SEC-MALLS Results:
[0046] Table 3
[0047] The results indicate a bimodal distribution, where high molecular weight HA dominates, contributing to superior viscoelastic properties.REFERENCES1. Boas NF. Isolation of hyaluronic acid from the cock’s comb. J Biol Chem. 1949; 181 (2):573- 575.2. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4-27.3. O’Regan M, Martini I, Crescenzi F, De Luca C, Lansing M. Molecular mechanisms and genetics of hyaluronan biosynthesis. Int J Biol Macromol. 1994;16(6):283-286.4. Xu Q, Torres JE, Hakim M, et al. Collagen-and hyaluronic acid-based hydrogels and their biomedical applications. Mater Sci Eng R Reports. 2021; 146: 100641.5. Marinho A, Nunes C, Reis S. Hyaluronic acid: a key ingredient in the therapy of inflammation. Biomolecules. 2021 ;11 (10):1518.6. Meyer K, Hobby GL, Chaffee E, Dawson MH. The hydrolysis of hyaluronic acid by bacterial enzymes. J Exp Med. 1940;71(2):137.7. Ricci M, Micheloni GM, Berti M, et al. Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis. Musculoskelet Surg. 2017;101:45-49.8. Graga MFP, Miguel SP, Cabral CSD, Correia I J. Hyaluronic acid — Based wound dressings:A review. Carbohydr Polym. 2020;241: 116364.9. Miller LE, Fredericson M, Altman RD. Hyaluronic acid injections or oral nonsteroidal antiinflammatory drugs for knee osteoarthritis: systematic review and meta-analysis of randomized trials. Orthop J Sport Med. 2020;8(1):2325967119897909.10. Pan NC, Pereira HCB, da Silva M de LC, Vasconcelos AFD, Celligoi MAPC. Improvement production of hyaluronic acid by Streptococcus zooepidemicus in sugarcane molasses. Appl Biochem Biotechnol. 2017;182:276-293.11. Mukasa-Mugerwa E. The camel (Camelus dromedarius): a bibliographical review.Published online 1981.
Claims
ClaimsIndependent Claims
1. A hyaluronic acid composition extracted from a novel animal-derived source [camel limbs], wherein the source comprises [specific animal tissue] and the composition retains its natural bioactivity and purity, making it suitable for biomedical, pharmaceutical and cosmetic applications.[Claim2] A method for extracting and purifying hyaluronic acid from a new animal source, comprising:• Processing the [camel limbs] to release hyaluronic acid;• Purifying the extracted hyaluronic acid by membrane filtration and size exclusion chromatography (SEC).• Adjustment of the molecular weight distribution by controlled depolymerization.• Characterization of the composition by size exclusion chromatography- multi-angle laser light scattering (SEC-MALLS), Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) to ensure purity, stability and functional integrity.[Claim3] A pharmaceutical or cosmetic formulation comprising the hyaluronic acid composition of claim 1, wherein the formulation is proposed for potential applications in tissue engineering and regenerative medicine, including wound healing, scaffold development and bio-compatible implants, sustained release drug delivery systems ensuring prolonged therapeutic effects, and dermatological applications, including hydration, anti-ageing and skin repair.[Claim4] A method for the potential use of the composition of claim 1 in intra-articular injection therapies, wherein the composition may support synovial fluid elasticity and reduce joint inflammation due to its biochemical properties.Dependent Claims[Claim5] The composition of claim 1 , wherein the molecular weight fraction distribution comprises 30.78 - 31.50% of HA molecules greater than 1,000,000 g / mol,21.11 - 21.64% of HA molecules between 500,000 - 1,000,000 g / mol, 18.64 - 19.70% of HA molecules between 200,000-500,000 g / mol, 27.36 -28.75% of HA molecules less than 200,000 g / mol, and 0.00% of HA molecules less than 20,000 g / mol.[Claim6] The composition of claim 1 , further comprising sodium hyaluronate at 79.9%, uronic acid at 38.6%, and sodium glucuronate at 43.0%.[Claim7] The method according to claim 2, wherein the extraction and purification process preserves the intrinsic bioactivity of HA by optimizing the de polymerization conditions.[Claim8] The pharmaceutical formulation according to claim 3, wherein the HA composition is contemplated for possible incorporation into sustained release microspheres, nanoparticles or hydrogel systems, allowing prolonged therapeutic action.[Claim9] The cosmetic formulation according to claim 3, wherein the HA composition is proposed for optimizing high transdermal absorption, which may improve skin penetration and prolonged hydration.[ClaimIO] The intra-articular injectable formulation of claim 3, wherein the HA composition is proposed for potentially improving joint lubrication, reducing friction, improving synovial fluid viscosity and relieving pain in patients with osteoarthritis.[Claiml 1 ] The composition according to claim 10, wherein the molecular weight and biochemical properties are considered with respect to potential effects on prolonged joint residence time, optimized diffusion into cartilage and increased bioavailability for orthopedic and rheumatologic applications. [Claim12] The method of claim 4, wherein the HA composition is contemplated for possible co-administration with an anti-inflammatory agent, platelet rich plasma (PRP) or corticosteroids to investigate their possible effects on therapeutic efficacy.
13. The composition according to claim 1, wherein the hyaluronic acid formulation is crosslinked by chemical or enzymatic processes, thereby prolonging the degradation time and optimizing joint lubrication.
14. The method of claim 4, wherein the composition is proposed for potentially stimulating endogenous HA production in synovial fibroblasts, which may contribute to reducing the long-term progression of osteoarthritis.
15. The pharmaceutical formulation of claim 3, wherein the HA composition is contemplated for potential use as a carrier for bioactive compounds in targeted drug delivery applications.
16. The composition of claim 1 further comprising bioactive compounds such as antioxidants, peptides or growth factors that may contribute to enhancing biological activity in regenerative medicine applications.[Claim17] A method for investigating potential improvements in the bioavailability and molecular integrity of hyaluronic acid, comprising administering the composition of claim 1 in a controlled release system to evaluate its stability and performance in biomedical and cosmetic applications.